X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway with X4P-001-IO

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today highlighted data from multiple presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The data, primarily generated from biopsies of tumors from melanoma patients, demonstrated important changes in the tumor microenvironment and the activation of tumor specific immune cell responses following oral administration of X4P-001-IO, an investigational CXCR4 antagonist. These data underscore the ability of X4P-001-IO to enhance immune surveillance, memory and activation through adaptive immune pathways (e.g., T-cells).

This entry was posted in Recent Development News: Q4 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »